- Home
- NXPL vs LSTA Comparison
NXPL vs LSTA Comparison
Compare NXPL & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPL | LSTA |
|---|---|---|
| Founded | 1997 | 1980 |
| Country | United States | United States |
| Employees | 130 | N/A |
| Industry | Telecommunications Equipment | Misc Health and Biotechnology Services |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 28.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NXPL | LSTA |
|---|---|---|
| Price | $6.05 | $0.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 19.6K | ★ 104.8K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.34 | $1.01 |
| 52 Week High | $8.37 | $5.07 |
Technical Indicators
Market Signals| Indicator | NXPL | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 14.19 |
| Support Level | $5.54 | N/A |
| Resistance Level | $7.14 | $2.19 |
| Average True Range (ATR) | 0.44 | 0.24 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 32.74 | 0.70 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.